United Laboratories International (HKG:3933) wholly owned subsidiary, Zhuhai United Laboratories, received approval from China's National Medical Products Administration to begin clinical trials of TUL321 capsules, according to a Thursday Hong Kong bourse filing.
TUL321 is a next-generation complement factor B inhibitor being developed for autoimmune and complement-mediated diseases, the filing said.